Scarica l'app Stockscreener
21.45
0.92%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SDGR Giù?
Forum
Previsione
Schrodinger Inc Borsa (SDGR) Ultime notizie
What analysts say about Schrödinger Inc. stockPhenomenal capital gains - Jammu Links News
Schrödinger Inc. Stock Analysis and ForecastMarket-leading growth rates - Jammu Links News
Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration - Yahoo Finance
When the Price of (SDGR) Talks, People Listen - news.stocktradersdaily.com
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
What drives Schrödinger Inc. stock priceRobust financial gains - Jammu Links News
Is Schrödinger Inc. a good long term investmentConsistently profitable trades - Jammu Links News
Schrodinger stock maintains Buy rating at Citi on Ajax collaboration By Investing.com - Investing.com Canada
Ajax Therapeutics and Schrödinger expand JAK inhibitor collaboration - Investing.com
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target - Stock Titan
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - Barchart.com
What makes Schrödinger Inc. stock price move sharplyMoney Making Low Risk Plans - beatles.ru
Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock - MSN
BMO Capital Remains a Buy on Schrodinger (SDGR) - The Globe and Mail
(SDGR) On The My Stocks Page - news.stocktradersdaily.com
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505 - MSN
Schrodinger stock rating assumed by Morgan Stanley at Equalweight - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc.SDGR - WV News
Schrödinger Demonstrates Corporate Sustainability Progress in 2024 Report - ReportAlert
Schrödinger gets Fast Track status for SGR-1505 - MSN
Schrödinger (SDGR) Gains FDA Fast Track for MALT1 Inhibitor - GuruFocus
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia | SDGR Stock News - GuruFocus
Schrödinger’s MALT1 inhibitor receives FDA fast track designation - Investing.com
Schrodinger Announces Board Elections and Approvals - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger - Bluefield Daily Telegraph
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | PRN_FinancialWrapper | PR Newswire - FinancialContent
Where are the Opportunities in (SDGR) - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, ... - Eagle-Tribune
Harbor Capital Advisors Inc. Grows Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger slides after early-stage trial data for cancer therapy - MSN
Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results - Seeking Alpha
Schrödinger (SDGR) Shares Dip After Initial Phase 1 Trial Data - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data fo - GuruFocus
Schrodinger Reports 22% Response Rate in Phase 1 Trial of SGR-1505 for B-Cell Cancers; Shares Fall - MarketScreener
Schrödinger stock slides on cancer trial data (SDGR:NASDAQ) - Seeking Alpha
Transcript : Schrödinger, Inc.Special Call - MarketScreener
Schrodinger (SDGR) Reports Promising Phase 1 Results of SGR-1505 | SDGR Stock News - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress - Eagle-Tribune
Day 9 of Gains Streak for Schrodinger Stock with 24% Return (vs. 38% YTD) [6/11/2025] - Trefis
Schrodinger Inc (SDGR) Trading 5.17% Higher on Jun 11 - GuruFocus
California State Teachers Retirement System Reduces Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of “Buy” from Analysts - Defense World
Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
Schrödinger's Stock in a Quantum State: Fraud Probe and Leadership Shake-Up Cloud the Outlook - AInvest
Schrodinger Inc (SDGR) Trading 4.34% Higher on Jun 6 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Schrodinger Shows Rising Price Performance With Jump To 82 RS Rating - Investor's Business Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect - ACCESS Newswire
4.17%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):